



The e-newsletter for the Indian Biotech industry

www.ableindia.in

August 2026 | Issue 0026

ABLE Governing Body Members

Hon. Non-executive Chairperson
Dr. Kiran Mazumdar-Shaw

Hon. President
Mr. G S Krishnan

Hon. Vice President
Ms. Deepanwita Chattopadhyay

Hon. General Secretary
Dr. Ezhil Subbian

Treasurer
Mr. Ravi Bhola

Governing Body members

Dr. Ashvini Shete

Dr. B N Manohar

Dr. Jayashree Aiyar

Mr. Krishna Kalyan T. D.

Mr. Sanjeev B Neelappa

Dr. S. Shriram


Ms. Sowmya L Balendiran

Dr. Vasan Sambandamurthy

Mr. Venkat K Bundla

Advisor & Editor
Mr. Narayanan Suresh

ABLE opens a BioBridge to Canada for biotech startups



Dear Members, Colleagues and Friends,

I am happy to inform members that ABLE is launching another landmark initiative with an international collaboration. ABLE will be conducting the **India-Canada BioBridge** with support from the High Commission of Canada in India. The BioBridge is designed to help growth-stage biotech startups and bio incubation managers to strengthen their commercialization capabilities, prepare for global markets and build strategic connections with the Canadian biotechnology ecosystem.

Our industry has its task cut out with the Niti Aayog report, “**The Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035**” projecting a national BioEconomy of \$691 billion by 2035. Further, the report projects the country’s BioEconomy to touch \$1.2 trillion in 2040 and \$2.6 trillion by 2047.

The roadmap has identified the key challenges, and presented a comprehensive plan to nudge the BioEconomy to these projected numbers in the next 10 to 15 years. I am happy to inform that several ABLE members were part of the expert committee that helped to prepare the report and ABLE Secretariat collated the inputs together and contributed to the exercise. With the big targets now gaining the attention of national policy makers, ABLE is confident that many of the existing regulatory hurdles can be addressed, paving the way for faster and more streamlined approvals for biotech products.

Biotech industry has emerged as the No.3 in the industrial sectors investing heavily in research. This was mentioned in the report on **Research and Development Statistics for 2023-24 prepared by the Department of Science & Technology (DST), Government of India**. For a growing biotech sector, this is a creditable achievement with the pioneers of our industry investing continuously in innovation to develop the products for the future.

ABLE is embarking on the next annual cycle of its flagship ‘**voice for BT**’ public speaking contest for college students across India and Southeast Asia. The preliminary rounds will be conducted across five regions: Western Region – Mumbai, Southern Region – Thanjavur, Northern Region – New Delhi, Eastern Region – Bhubaneswar and International (ASEAN) – Kuala Lumpur. The **BEST Awards** will be conducted simultaneously across the four Indian regions to identify and recognize the most innovative ideas.

The last quarter is buzzing with activities from ABLE and we would like all our members to proactively participate and contribute to the growth of biotechnology in India.

G S Krishnan
Hon. President, ABLE

IN THIS ISSUE

- India prepares \$691 billion BioEconomy Roadmap for 2035
- Applications Open for 'voice for BT' & 'BEST' 2026
- Participate in "Innovating Multiomics: The Future Begins with Better Samples"
- ImmunitoAI Wins the Indo-Boston Biotech Bridge Award
- ABLE at the CEO Breakfast Meet with the Hon'ble Chief Minister of Karnataka
- Strengthening India-Canada Biotech Collaboration: A Productive Meeting with the Government of British Columbia
- Industry News

India prepares \$691 billion BioEconomy Roadmap for 2035



By Narayanan Suresh

India aims to more than treble its BioEconomy to \$691 billion from the current \$195 billion with an ambitious roadmap that seeks to increase innovation, speed up regulatory mechanisms, provide a \$5.8 billion special biotech fund and prepare the country for a new biological age.

These plans are part of the **“Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035”** prepared by the national think tank, Niti Aayog. The report was released by the Minister for S&T Dr. Jitendra Singh in New Delhi on 16th July 2026. An Expert committee that consisted of Dr. Kiran Mazumdar-Shaw; Dr. Soumya Swaminathan; ABLE President, Mr. G S Krishnan, and former ABLE Presidents Dr. Vijay Chandru, Dr. P M Murali, provided all the technical inputs for the report prepared by the Niti Frontier Tech Hub headed by Dr. Debjani Ghosh. ABLE Secretariat (Association of Biotechnology Led Enterprises) anchored the biotech industry views for the report.

Releasing the report, Minister Dr. Jitendra Singh said the government will facilitate the implementation of the key suggestions of the report that seeks to push the national BioEconomy by 3.5 times to \$691 billion by 2025 and further \$2.6 trillion by 2047. At this level, the BioEconomy will create 30 to 35 million high value jobs in the country.



Giving industry views, ABLE President Mr. Krishnan highlighted how the industry is geared to achieve these ambitious numbers in the next 9 years. He urged the government to carve out the ₹ 50,000 crore BioEconomy Growth Fund from within the RDI fund to help the innovative companies. India has the opportunity to leapfrog in BioEconomy and the cost of missing out this opportunity will impact national security, loss of global leadership position, severe setbacks to environment, and loss of employment opportunities.

The roadmap has recommended formation of six key time-bound National BioMissions: GeneIndia, AgriBio 2.0, BioX Foundry, OneHealth, Marine Biotechnology and BioPharma Next to boost the national BioEconomy towards the goals. All these missions will involve multiple government ministries and agencies. Hence the formation of a high-level Empowered Committee on National Bio Missions has been recommended as part of the roadmap.

Expert committee member, Dr. Souwmya Swaminathan, urged the government to speed up the regulatory mechanisms so that our innovators could quicken the pace of product development using the latest tools such as AI (artificial intelligence). She referred to the immense potential of the country's ecosystem that has recently got global approval for the first new antibiotic in 50 years.

Please [click here](#) to view the document.



Applications Open for 'voice for BT' & 'BEST' 2026

ABLE is pleased to announce that applications are now open for the 2026 editions of its flagship student engagement programs – 'voice for BT', Inter-collegiate biotechnology public speaking competition, and the **Biotechnology Entrepreneurship for Student Teams (BEST) Awards**, a unique platform that nurtures innovation and entrepreneurship among biotechnology students.

Biotechnology Entrepreneurship for Student Teams (BEST) Awards



The graphic features the ABE logo (Association of Biotechnology Led Enterprises) with the tagline 'Pursuing Infinite Opportunities' and the Novonosis logo, stating 'Supported by'. The central focus is the 'best awards' logo, which includes the text 'BIOTECHNOLOGY ENTREPRENEURSHIP FOR STUDENT TEAMS'. Below this, a section titled 'TAKE YOUR INNOVATE IDEA TO THE NEXT LEVEL >>>>' lists five bullet points: 'Fostering Biotech Entrepreneurship', 'Open to graduate, postgraduate, and doctoral students', 'From Concept to Solution', 'Form a Team of 3 & Get Shortlisted for the Zonal Rounds', and 'Learn from Industry & Academic Experts Pitch Your Idea & Win Exciting Prizes'. The website 'www.ableindia.in/best' is provided. At the bottom, 'REGIONAL ACADEMIC PARTNERS' are listed with logos for Amity University, SASTRA Deemed to be University, KIIT University, and D.Y. Patil University.

The **BEST Awards** are designed to foster an entrepreneurial mindset among biotechnology students by encouraging them to develop innovative solutions to real-world challenges. The competition is open to final-year undergraduate, postgraduate, and doctoral students in biotechnology and allied disciplines. Participating teams, comprising three students from the same or different institutions, will present their innovative ideas before an eminent jury in a confidential evaluation session. The competition provides valuable exposure to the fundamentals of technology commercialization, intellectual property, regulatory pathways, and entrepreneurship. The top two teams from each zonal round will receive cash awards and recognition.

APPLY TODAY www.ableindia.in/best

'BEST' Program Schedule

- West Zonal round will be held on 20th August at DY Patil University, Navi Mumbai, Maharashtra
- South Zonal round will be held on 10th September at SASTRA Deemed to be University, Thanjavur, Tamil Nadu
- North Zonal round will be held on 8th October at Amity University, Noida, Uttar Pradesh
- East Zonal round will be held on 27th October at KIIT University, Bhubaneswar, Odisha

'voice for BT'



'voice for BT' is an Inter-collegiate public speaking competition dedicated to biotechnology. The competition provides an excellent platform for students to express their perspectives on emerging biotechnology topics while enhancing their communication and leadership skills. The competition is open to final-year undergraduate and first-year postgraduate students in life science disciplines. Each participating institution may nominate one student to represent the college. Participants are evaluated by an eminent panel comprising leading scientists, academicians, and industry experts. The competition is conducted across all four regions of India, with an International (ASEAN)

edition bringing together finalists from India and ASEAN. The top two winners will qualify for the prestigious "International Grand Finale – 'voice for BT' 2026".

APPLY TODAY www.ableindia.in/voicebt.

'voice for BT' - Zonal Schedule

- **West Zone:** 21 August 2026 – DY Patil University, Navi Mumbai, Maharashtra
- **South Zone:** 11 September 2026 – SASTRA Deemed to be University, Thanjavur, Tamil Nadu
- **International (ASEAN) Edition:** 18 September 2026 – Sunway University, Kuala Lumpur, Malaysia
- **North Zone:** 9 October 2026 – Amity University, Noida, Uttar Pradesh
- **East Zone:** 28 October 2026 – KIIT University, Bhubaneswar, Odisha

The program is supported by **Novonosis**, **Biocon** and **Inceptbio**.



We invite biotechnology students and institutions across the country to participate in these prestigious initiatives and be part of a vibrant platform that celebrates scientific excellence, innovation, entrepreneurship and effective science communication.

Participate in "Innovating Multiomics: The Future Begins with Better Samples"

25th August | TAJ MG Road, Bengaluru



We are pleased to invite you to “**Innovating Multiomics: The Future Begins with Better Samples,**” a one-day focused symposium in Bengaluru, jointly organised by **Covaris**, its India partner **Premas Life Sciences**, and the **Association of Biotechnology Led Enterprises (ABLE)**. With the rapid evolution of multiomics, the importance of high-quality sample preparation has become increasingly critical in enabling accurate and meaningful biological insights. The workshop will bring together **thought leaders, technical experts and key decision-makers** from clinical research and diagnostics, pharma and biopharma, CROs and academia to explore the evolving landscape of analytical sample preparation for both human and non-human sample types.

Key areas of discussion will include:

- Standardized and high-quality sample preparation across multiomics.
- Sample-prep challenges in clinical, pharma/biopharma, CRO and academic settings.
- Best practices for nucleic acid, chromatin and proteomics workflows.
- Sample preparation for diverse sample types, including blood, FFPE, plant and microbial samples.
- Covaris AFA®-enabled workflows across NGS, epigenomics and proteomics.

We encourage you to register and be part of this focused forum bringing together the life sciences community to discuss how better sample preparation can enable more reliable and impactful multiomics research.

FREE REGISTRATION

ImmunitoAI Wins the Indo-Boston Biotech Bridge Award



We are delighted to announce **ImmunitoAI** as the winner of the inaugural **Indo-Boston Biotech Bridge Award** — a collaboration between **Nucleate India**, **ABLE – Association of Biotechnology Led Enterprises**, and **LabCentral**.

ImmunitoAI is pioneering a new approach to **therapeutic antibody discovery**, using a proprietary structure-first AI platform to design de novo antibodies directly from antigen structures. Their innovative approach has the potential to address challenging and previously undruggable targets while accelerating the journey

from discovery to therapeutic development.

This award comes at an exciting stage in ImmunitoAI's journey as the company takes its platform and early assets towards the **global biotech ecosystem**.

As part of the award, the ImmunitoAI team will join **LabCentral Loop Week in Cambridge, Massachusetts, from September 14–22**, connecting with founders, investors, pharmaceutical leaders, and the broader Kendall Square biotech community.

For ImmunitoAI, this is an opportunity to build strategic partnerships, engage with experienced mentors, and establish relationships that can help move their technology from platform validation towards global commercialisation.

Congratulations to the entire ImmunitoAI team!

ABLE at the CEO Breakfast Meet with the Hon'ble Chief Minister of Karnataka



ABLE participated in the **CEO Breakfast Meet** hosted by the **Department of Electronics, IT, BT and S&T, Government of Karnataka**, with the **Hon'ble Chief Minister of Karnataka D. K. Shivakumar**, marking the formal announcement of **Bengaluru Tech Summit (BTS) 2026**.

Representing ABLE, **Mr. G S Krishnan, Hon. President**, highlighted the significance of the recently launched **NITI Aayog Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035**, which ABLE supported in coordination with NITI Aayog. He noted that the roadmap identifies **Bengaluru as a potential BioEconomy Growth Hub by 2035**, with the capacity to contribute nearly **25% of India's BioEconomy**.

Mr. Krishnan emphasized Karnataka's strengths in **cell and gene therapy, genomics, biopharmaceuticals, synthetic biology, AI-driven biotechnology, and the Blue BioEconomy**, while underscoring the importance of leveraging the State's robust innovation ecosystem and sustained government support to reinforce its leadership in biotechnology and future biomanufacturing. He also highlighted emerging opportunities in the Blue BioEconomy, including **seaweed cultivation and biofuels**.

Further, he showcased Karnataka's leadership across the **bioindustrial, bioservices, and bioagriculture** sectors, driven by initiatives such as **K-Tech, Elevate, R&D funding, bio-innovation programmes, and regional biotech hubs**.



He reaffirmed that continued policy support and strong industry-government collaboration will be essential to sustaining Karnataka's leadership in India's biotechnology landscape.

During the interactive discussion, **ABLE members** emphasized the need for continued government

support to accelerate investments in **biomanufacturing**, strengthen infrastructure, and foster innovation across the biotechnology ecosystem.

Strengthening India-Canada Biotech Collaboration: A Productive Meeting with the Government of British Columbia



It was a pleasure hosting **Mr. Prashanth Nair, Managing Director-India** and **Mr. Prateek Bhatia, Trade Commissioner** from the **Government of British Columbia** at the ABLE office for an engaging and productive discussion on strengthening India-Canada collaboration in the biotechnology ecosystem.

We explored opportunities to foster innovation, build strategic partnerships and create meaningful avenues for startups and the broader life sciences community. It was also exciting to discuss the upcoming Canada Fund for Local Initiatives (CFLI) project and its potential to further support collaborative initiatives and ecosystem development.

Looking forward to working together to drive impactful partnerships between India and British Columbia and advance innovation across the biotech sector.

Industry News

Biotech No.3 in Industry R&D spends

The biotechnology industry has emerged as the third ranked sector in investing in research in 2023-24, according to a report released by the Department of Science & Technology (DST), Government of India.

Biotechnology industry got the 3rd rank by spending ₹ 10,321 crore. The first two spots were taken transport companies (₹ 39,137 crore), and drugs and pharmaceuticals (₹ 25,487 crore). The much bigger IT and software industry ranked No. 4 with ₹ 9,587 crore). Electrical and electronics sector stood 5 in the ranking spending ₹ 6,779 crore).

A report in The Hindu newspaper indicated that though DST tracked 8,000 companies for the research spends, 90% of the investments in research came from just 500 companies. The results were part of the DST Research and Development Statistics 2025-26. Another highlight was that now private industry employs more full-time equivalent researchers than the government institutions. It was the reverse till 2019-20.

In all, private sector that includes private companies, scientific and industrial research organizations and private higher educational institutions, spent a total of ₹ 127,000 crore for research in 2023-24. Of this, educational institutions contributed ₹ 9,164 crore).

Syngene Inaugurates Clinical Translational Sciences Laboratory in Bengaluru



Syngene International has inaugurated its Clinical Translational Sciences Laboratory in Bengaluru, marking a significant step towards advancing translational research and accelerating the development of precision medicine. The facility was inaugurated in the presence of Dr. Kiran Mazumdar-Shaw, Executive Chairperson, Mr.

Siddharth Mittal, CEO, and members of the company's leadership team. The new laboratory has been established with the vision of bridging discovery research and clinical operations to deliver meaningful outcomes for patients. By integrating real patient samples with translational science, the facility aims to accelerate the transition from data generation to informed clinical decision-making. The laboratory is expected to enhance Syngene's capabilities in connecting discovery, development, and clinical research through an integrated continuum, enabling deeper biological insights, improved patient stratification, and more efficient clinical development programmes

for global clients. Designed to go beyond conventional data generation, the Clinical Translational Sciences Laboratory seeks to enable earlier disease detection, identify the right patients for targeted therapies, and bridge the longstanding gap between scientific discovery and clinical application, ultimately contributing to improved patient outcomes.

[*Read more: Syngene International*](#)

Biocon launches biosimilar Yesafili in the US to treat eye disorders



On August 3, 2026 Biocon has commercially launched **Yesafili™ (aflibercept-jbvf)** in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference

product EYLEA® (aflibercept) 2 mg. Biocon had got the US regulator FDA approval for the product in May 2024.

About the launch, **Dr Shreehas Tambe, CEO & Managing Director, Biocon Ltd.**, said, “The launch of Yesafili™ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea® 2 mg, advancing access to life-changing medicines for patients around the world.”

An estimated 19.8 million Americans are living with age-related macular degeneration (AMD) while U.S. sales of aflibercept reached approximately \$5.89 billion in 2023 underscoring the growing need for effective treatment options. Macular degeneration, specifically age-related macular degeneration (AMD), is a significant health concern, especially as the population ages. It is a leading cause of irreversible vision loss in adults over 60.

Dr Reddys gets FDA approval for biosimilar Rituximab



Dr.Reddy's

ABLE patron gold member, Dr Reddy's Laboratories has got the US regulator, FDA approval for Rituxan, a biosimilar to rituximab, a monoclonal antibody to treat a variety of autoimmune diseases, that includes non-Hodgkin Lymphoma.

The product was developed, manufactured and submitted for approval by Dr. Reddy's Laboratories.

The approval follows the successful recent Pre-License Inspection (PLI) conducted by the U.S. FDA at the Company's biologics manufacturing facility in Bachupally, Hyderabad, and reflects the company's capabilities in bringing complex biologic medicines to highly regulated markets and its long-standing commitment to biosimilars.

Under a commercialization agreement, Fresenius Kabi holds the exclusive rights to commercialize the product in the United States, one of the world's most important pharmaceutical markets.

"The approval of the rituximab biosimilar on the FDA's goal date reflects our capabilities in developing and manufacturing complex biologic medicines for global markets," said Dr. Sridevi Khambhampaty, Global Head, Biologics, Dr. Reddy's Laboratories.

The rituximab biosimilar has been commercialized in India, the European Union, the United Kingdom and more than 25 emerging markets, and has also received marketing approval in Switzerland and Canada.

Aurobindo Pharma Inaugurates TheraNym - Pioneering India's Large-Scale Biologics Contract Manufacturing Facility



Aurobindo Pharma has inaugurated TheraNym, one of India's largest dedicated biologics contract manufacturing organisations (CMOs), at Borapatla near Hyderabad. The state-of-the-art facility marks the company's strategic expansion into biologics manufacturing and has MSD as its anchor customer. Designed to

meet global regulatory standards, TheraNym features advanced bioreactors, downstream processing, aseptic fill-finish capabilities, and quality control laboratories to support the production of biologic therapies for domestic and international markets. The facility reinforces India's growing role in the global biologics supply chain and strengthens Telangana's position as a leading biotechnology and biomanufacturing hub.

Read more: [Aurobindo Pharma](#)

Immuneel and THSTI Partner to Advance Cell and Gene Therapies in India



Immuneel has entered into a strategic partnership with the Translational Health Science and Technology Institute (THSTI) to strengthen India's capabilities in advanced cell and gene therapies. The collaboration combines Immuneel's expertise in CAR-T cell therapy development and manufacturing with THSTI's translational research capabilities to

accelerate innovation in CAR-T therapies and indigenous lentiviral vector manufacturing. The partnership aims to advance next-generation therapies, promote translational research and technology transfer, and build globally competitive capabilities that improve access to advanced therapies for patients in India and worldwide.

Read more: [Immuneel Therapeutics](#)

Fibroheal Raises ₹14 Crore to Expand Global Footprint



Bengaluru-based Fibroheal Woundcare Pvt. Ltd. has raised ₹14 crore in fresh funding to accelerate its global expansion and strengthen its leadership in advanced silk biomaterial-based wound care. The investment will support

the company's commercial growth, regulatory readiness, international market expansion, and development of next-generation biomaterial technologies. Fibroheal's products are currently used in over 500 hospitals across India, having treated more than 150,000 patients, further reinforcing India's growing position in MedTech innovation.

Read more: [India Pharma Post](#)

ABLE Welcomes Its New Members

(International Member)



Covaris®
a PerkinElmer Company

ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES (ABLE)

Comments and questions are welcome and should be addressed to:

Email

info@ableindia.org.in

Website

www.ableindia.in

Twitter

LinkedIn

Address

No.123/C, 16th
Main Road 4th
Block, 5th Cross,
Koramangala,
Bangalore-560 034,
India

Tel.:

+91-80-41636853



FOCUS AREAS



www.ableindia.in